NYSE:DHR
NYSE:DHRLife Sciences

Danaher’s 19.6% Rally Sparks Debate After Portfolio Moves and Diagnostics Growth in 2025

If you have been eyeing Danaher stock lately and wondering what to do next, you are certainly not alone. It is one of those names that frequently finds itself at the center of investor debates, especially after sharp price swings. Over the last month, Danaher has bounced back with an impressive 19.6% gain, recouping much of the ground lost earlier this year. In a shorter timeframe, just in the past week, the stock is up another 6.1%. Despite those recent gains, the year-to-date total return...
NYSE:CRI
NYSE:CRILuxury

Carter’s (CRI) Net Margin Drops to 4.7%, Underscoring Profitability Concerns

Carter's (CRI) reported a net profit margin of 4.7%, down from 8.1% a year ago, and annual earnings have declined by 6.8% over the past five years. Revenue is set to decrease by 1.1% per year over the next three years, while recent earnings growth remains negative. With the stock trading at a Price-To-Earnings ratio of 9.1x, notably lower than the industry average, investors are weighing the value case against ongoing pressure on margins and profits. See our full analysis for Carter's. Next,...